We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 561

The competition and IP intersect
  • King & Wood Mallesons
  • Australia
  • February 13 2014

In a move which will be closely watched by the pharmaceutical industry, the ACCC has commenced proceedings against Pfizer alleging breaches of the

Interim authorisation granted to eRx script
  • Gilbert + Tobin
  • Australia
  • February 28 2013

The ACCC granted interim authorisation to eRx Script Exchange to allow it to enter into a contract with MediSecure to facilitate interoperability

BaxterGambro gets ACCC tick of approval
  • King & Wood Mallesons
  • Australia
  • September 5 2013

Adding to the regulatory approvals in China (blogged about in our previous post), New Zealand and Europe, the ACCC has announced that it will not

Competition regulators continue their campaign against pharmaceutical companies
  • King & Wood Mallesons
  • Australia, USA
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

European Commission ups the cost of paying for delay
  • King & Wood Mallesons
  • Australia, European Union, USA
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think
  • King & Wood Mallesons
  • Australia
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18

ACCC proposes to reauthorise collective negotiations by rural doctors
  • Corrs Chambers Westgarth
  • Australia
  • September 11 2013

On 28 August 2013, the ACCC issued a draft determination proposing to allow the Rural Doctors Association of Australia (RDAA) and its state

ACCC conditionally clears NestlePfizer deal
  • Herbert Smith Freehills LLP
  • Australia
  • November 30 2012

On 22 November 2012, the Australian Competition and Consumer Commission (ACCC) announced it would not oppose the proposal by Nestlé SA to acquire the global infant nutrition business of Pfizer Inc (the transaction), subject to court enforceable undertakings

ACCC issues report on private health insurance
  • Gilbert + Tobin
  • Australia
  • March 31 2013

The ACCC report on 'anti-competitive and other practices by health funds and providers in relation to private health insurance' has been tabled in

ACCC halts hospital merger
  • King & Wood Mallesons
  • Australia
  • June 18 2014

Healthscope is owned by private equity houses. It is Australia's largest private hospital owner, with 44 hospitals in Australia (and approximately 81